Relief for SII as court rejects trademark-violation plea over `Covishield'
On January 4, Cutis-Biotech, a pharmacertical firm, filed a suit in the civil court claiming it was a prior user of the brandname Covishield, and sought to restrain SII from using the name.
A local court has rejected an application seeking injunction against the use of `Covishield' as brandname by the vaccine-maker Serum Institute of India (SII), the company said on Saturday.
SII is producing a coronavirus vaccine named Covishield, co-developed by the University of Oxford and British-Swedish company AstraZeneca. The Indian government has purchased 11 million doses of Covishield vaccine.
While the court order was not available immediately, the lawyer of Cutis-Biotech, which had filed the suit, said it would file an appeal in the high court.
On January 4, Cutis-Biotech, a pharmacertical firm, filed a suit in the civil court claiming it was a prior user of the brandname Covishield, and sought to restrain SII from using the name.
SII had told the court that the two companies operate in different product categories and there is no scope for confusion over the trademark.
"Court has rejected the application," said SII's lawyer Hitesh Jain.
Advocate Aditya Soni, lawyer of Cutis-Biotech, said the order copy was not yet available, but operative order was read out in the court. "We will file an appeal against the order in the high court," he said. PTI COR KRK KRK
